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Metabolomic and lipidomic 
plasma profile changes in human 
participants ascending to Everest 
Base Camp
Katie A. o’Brien1,2, R. Andrew Atkinson  3, Larissa Richardson4, Albert Koulman4, 
Andrew J. Murray2, Stephen D. R. Harridge1, Daniel S. Martin5,6, Denny Z. H. Levett7,8, 
Kay Mitchell7,8, Monty G. Mythen9, Hugh E. Montgomery  5,10, Michael P. W. Grocott7,8, 
Julian L. Griffin11 & Lindsay M. Edwards1,12
At high altitude oxygen delivery to the tissues is impaired leading to oxygen insufficiency (hypoxia). 
Acclimatisation requires adjustment to tissue metabolism, the details of which remain incompletely 
understood. Here, metabolic responses to progressive environmental hypoxia were assessed through 
metabolomic and lipidomic profiling of human plasma taken from 198 human participants before and 
during an ascent to Everest Base Camp (5,300 m). Aqueous and lipid fractions of plasma were separated 
and analysed using proton (1H)-nuclear magnetic resonance spectroscopy and direct infusion mass 
spectrometry, respectively. Bayesian robust hierarchical regression revealed decreasing isoleucine 
with ascent alongside increasing lactate and decreasing glucose, which may point towards increased 
glycolytic rate. Changes in the lipid profile with ascent included a decrease in triglycerides (48–50 
carbons) associated with de novo lipogenesis, alongside increases in circulating levels of the most 
abundant free fatty acids (palmitic, linoleic and oleic acids). Together, this may be indicative of fat 
store mobilisation. This study provides the first broad metabolomic account of progressive exposure to 
environmental hypobaric hypoxia in healthy humans. Decreased isoleucine is of particular interest as a 
potential contributor to muscle catabolism observed with exposure to hypoxia at altitude. Substantial 
changes in lipid metabolism may represent important metabolic responses to sub-acute exposure to 
environmental hypoxia.
Reduced cellular oxygen availability (hypoxia) is a feature of many disease states. Oxygen delivery may be globally 
impaired by diseases of the heart or lung, or by anaemia (in which the concentration of oxygen-carrying haemo-
globin is reduced); or regionally or locally impaired by macrovascular and microvascular disease respectively1,2. 
Diffusion of oxygen in the lungs and/or tissues may be impaired through accumulation of parenchymal fluid and/
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or inflammatory changes1. Meanwhile, ascent to high altitude resulting in exposure to environmental hypobaric 
hypoxia may also reduce tissue oxygen availability: the associated fall in barometric pressure is in turn associated 
with a decrease in the inspired partial pressure of oxygen (PO2). Increasing numbers of lowlanders travel to high 
altitude destinations, whilst ~7% of the world’s population (440 million people) reside above 1500 m3).
Adjustment to hypoxic conditions (acclimatisation) involves responses that mitigate reduced oxygen deliv-
ery, including an increase in minute ventilation and erythropoiesis4. Acclimatisation also requires a metabolic 
response to help match ATP synthesis and demand in the face of decreased oxidative capacity and increased 
oxidative stress5–7.
To date, studies examining metabolic acclimatisation in healthy human lowlanders have predominantly 
focused upon tissue specific responses, particularly those of skeletal muscle. These suggest a shift away from 
oxidative processes including β-oxidation, TCA cycle activity and oxidative phosphorylation (reviewed in5) and 
towards increased reliance upon carbohydrate metabolism. Enhanced glycolytic capacity has been suggested by 
increased intramuscular levels of glycolytic intermediates8 and hypoxic inducible factor 1-α (HIF-1α) mediated 
upregulation of glucose transporters and glycolytic enzymes9,10.
Hypoxia-induced alterations to lipid storage and mobilisation include a fall in circulating high density lipo-
proteins alongside increased triglyceride (TG) concentrations11, inhibition of lipoprotein lipase activity12 and sup-
pression of de novo lipogenesis13,14. These responses are likely to be mediated at the transcriptional level through 
HIF-1/2α15–17 and may be affected by changes in circulating catecholamines6,11, which are known to stimulate 
lipolysis via hormone sensitive lipase18. In addition, a transcriptional regulator of fatty acid oxidation in the liver, 
heart and muscle, peroxisome proliferator activated receptor α (PPARα), has been identified as a key regulator of 
hypoxic metabolic remodeling processes, with the metabolic adaptations of native high altitude Sherpa popula-
tions being linked to a putatively advantageous allele for the PPARα gene8,19,20.
Whilst details on metabolic acclimatisation to hypoxia are emerging, there are profound differences between 
studies in the duration and degree of hypoxic exposure5, which tends to be applied to highly selected, small 
groups of participants (e.g.21,22). Amongst those involving larger cohorts, there has been a failure to use standard-
ised ascent profiles23–25. Further, many studies have been tissue-specific, with little attention paid to circulating 
features indicative of global systemic metabolic responses.
Metabolomic and lipidomic analyses of biofluids measure a large number of variables of interest within the 
metabolic and lipid systems, thus providing a sensitive measure of functional biological phenotype (reviewed 
in26). The power of such analyses has been demonstrated in the identification of biomarkers related to the diag-
nosis or prognosis of a range of diseases27. The application of such methodology to the examination of responses 
to human hypobaric hypoxia has the potential to elucidate a metabolic signature of altitude exposure28,29. The few 
studies that have adopted this approach in the context of high altitude exposure have again employed small, select 
study cohorts30,31.
In order to better describe the human response to hypobaric hypoxia, we thus performed a large scale pro-
spective metabolomic and lipidomic analysis of plasma samples taken from 198 participants across 5 timepoints 
upon their ascent to Everest Base Camp (EBC, 5,300 m) as part of the Caudwell Xtreme Everest expedition32.
Methods
The study design, risk management plan and individual protocols for the Caudwell Xtreme Everest (CXE) 
Expedition were approved by the University College London (UCL) Research Ethics Committee (in accordance 
with the declaration of Helsinki). All methods were performed in accordance to relevant guidelines and regula-
tions. The study was designed and conducted by the UCL Centre for Altitude Space and Extreme Environment 
Medicine (CASE). Both verbal and written informed consent was obtained from all participants.
participants. Details on subject recruitment and characteristics have been outlined previously32. Briefly, 
participants included males and females aged over 18 with no upper age limit, who were required to pass two 
separate health screening stages32. From this screening process, 198 healthy volunteers participated in the study.
Study design. Ascent profiles, details on logistics as well as barometric pressure (PB), inspired partial pres-
sure of oxygen (PiO2) and temperature at the respective altitude laboratories have been reported previously32. 
Baseline measurements were performed in London (LDN) in a laboratory at UCL (75 m above sea level, PiO2 
19.7 KPa) between January 4th and February 26th 2007. Field studies were performed between 31st March and 6th 
June 2007 at laboratories set up at the following locations (altitudes expressed as meters, m): Kathmandu (KTM, 
1,300 m, PiO2 16.8 KPa), Namche (NAM, 3,500 m, PiO2 12.7 KPa), Pheriche (PHE, 4,250 m, PiO2 11.6 KPa) and 
Everest Base Camp (EBC, 5,300 m, PiO2 9.9 KPa). Data collection, including plasma sample collection, was per-
formed at each of these time points.
All participants underwent an identical ascent profile, arriving at EBC on day 11. To maintain an identical 
pattern of hypoxic exposure, participants’ movements were restricted on rest days, such that no subject ascended 
or descended more than 300 vertical meters from the laboratory altitude. The total trekking distance achieved 
over 11 days from Lukla airport to EBC was 50.7 km, with 5 days of rest over this course. The distance covered per 
day, taken at a gentle pace over the course of the day, was thus as follows: Lukla to NAM 9.1 km/day, NAM to PHE 
10.3 km/day, PHE to EBC 5.9 km/day.
Physiological variables. Body weight and arterial O2 saturation (SpO2), were determined prior to any oral 
intake on the morning that blood samples were obtained6.
Plasma Sample Analysis. Blood sampling. All blood samples were taken on a rest day the morning after 
arrival at each altitude location, being a minimum of 16 hours post exercise. Subjects were in a rested, fasting 
state and blood was taken from the antecubital vein and collected in 10 ml BD ethylenediamine-tetra-acetic acid 
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(EDTA) blood tubes (Southern Syringe Services LTD). Plasma was separated from blood cells by centrifugation 
of whole blood at 800 g for 15 min and immediately frozen in 1 ml aliquots in liquid nitrogen. Samples were kept 
below −80 °C until analysis.
Plasma preparation. Plasma samples were defrosted at room temperature. A 1:1:1 extraction was performed33, 
with 500 µl of methanol (Hypergrade for LC-MS, Merck) and 500 µl of chloroform (HiPerSolv Chromanorm 
for HPLC, VWR international), both ice cold, being added to 500 µl of plasma in a 1.5 ml Eppendorf. This was 
vortexed for 2 min, left to stand at −20 °C for 30 min, and then centrifuged for 3 min at 9100 g (Force 1624 
Microcentrifuge) to yield upper (methanol/aqueous, fraction) and lower phases (chloroform/lipid, fraction). 
700 µl of the upper phase and ~200 µl of the lower phase were pipetted into Eppendorf tubes for nuclear magnetic 
resonance spectroscopy (NMR) and mass spectrometry analysis, respectively.
Upper phase/methanol fraction. The upper fraction was dried down at 30 °C for 4 hours using a vac-
uum centrifuge (Eppendorf Concentrator 5301) and then re-suspended in 600 µl of the following NMR 
buffer: double distilled H2O containing 5% D2O for NMR (Acros organics, CAS: 7789-20-0) and 1 mM 
3-trimethylsilyl-1-propanesulfonic acid sodium salt (DSS) (Aldrich, 178837-5 G). D2O was required for the mag-
netic lock frequency and DSS was used as a chemical shift reference. The resulting solution was transferred to 
5 mm NMR tubes within a 96-tube rack.
Proton (1H-) NMR spectral acquisition and processing. 1H-NMR spectra of plasma samples were obtained using 
a Bruker Avance III 700 MHz spectrometer (Bruker Biospin, Karlsruhe, Germany) as described previously34. All 
samples were analysed on a participant by participant basis, meaning that plasma taken from the same participant 
at all 5 time points was defrosted and treated at the same time and run within the same NMR experiment. This 
was to ensure any daily differences in experimental procedure were removed from analysis when data between 
time points were compared.
Resulting spectra were processed using TopSpin (Bruker, Karlsruhe, Germany). Spectra were converted from 
time to frequency domain using a Fourier transform. The phase was adjusted and spectra aligned so that the DSS 
peak corresponded to 0 ppm through use of the icoshift program in Matlab35. Due to the degree of noise present, 
the aromatic region was excluded and only the aliphatic spectral region analysed. Normalisation and scaling of 
this spectral region were performed through use of Probabilistic Quotient normalisation36 and Pareto scaling37, 
respectively (Supplementary Fig. 1).
Initial principal components analysis (PCA) on this region revealed a separation into two regions that was not 
due to variation dependent on the experiment i.e. a change with location and thus with altitude (Supplementary 
Fig. 2). Instead, it was likely due to sample acquisition differences such as slight alterations in gain between NMR 
batch runs, as the samples were run in two batches at different times. A bias trend was identified to capture 
77% of this variance (Supplementary Fig. 3) and was subsequently normalised using EigenMS (Supplementary 
Fig. 4)38–40. As all samples from any single subject were run at the same time, they were contained within one of 
the two batch effect groups.
Following this, the full resolution spectra were binned at a ratio of 10:1. This ratio was found to sufficiently 
reduce the size of the data set, whilst retaining maximal information. The total number of bins was 1203. Putative 
identification of the metabolites associated with the peaks undergoing significant changes was undertaken using 
Chenomx software (Chenomx NMR Suite 7.1).
Lower phase/lipid fraction analysis by direct infusion mass spectrometry (DIMS). All solvents used were of 
LC-MS grade or better and were ordered from Sigma Aldrich (Gillingham, UK). Quality controls (QC’s) were 
derived from pooling all samples and serially diluting with chloroform. Internal standards for key lipid species or 
blanks (either PBS or chloroform) were prepared to run alongside the sample lipid fraction. All internal standards 
were obtained from Avanti Polar Lipids (Alabaster, AL, USA) with the exception of undecanoic acid and trilaurin 
(Sigma Aldrich).
The sample, QC’s and blanks (30 µl) were placed in a pre-defined random order across 96-well plates 
(Plate+, Esslab, Hadleigh, UK). To this, 750 µl methyl tert-butyl ether (MTBE) was added, along with 150 µl 
of internal standard mix, containing the following six internal standards: 1,2-di-o-octadecyl-sn-glycero-3-p
hosphocholine (0.6 µM), 1,2-di-O-phytanyl-sn-glycero-3-phosphoethanolamine (1.2 µM), C8-ceramide 
(0.6 µM), N-heptadecanoyl-D-erythro-sphingosylphosporylcholine (0.6 µM), undecanoic acid (0.6 µM), and tri-
laurin (0.6 µM). The blanks remained as such through addition of 150 µl chloroform instead of internal standard. 
The plate was subsequently shaken for 30 s.
Using a VIAFLO 96/384 electronic pipette (Integra), 25 µl of the resulting sample mixture was transferred to a 
glass coated 384 well plate and 90 µl mass spectrometry (MS) mix [7.5 mM NH4Ac IPA:MeOH (2:1)] added. The 
plates were then sealed using Corning aluminium micro-plate sealing tape (Sigma Aldrich Company, UK) and 
kept at −80 °C until required for DIMS analysis.
Lipidomics was performed as described previously41 using chip-based nanospray with an Advion TriVersa 
Nanomate (Advion, Ithaca, USA) interfaced to the Thermo Exactive Orbitrap (Thermo Scientific, Hemel 
Hampstead, UK). Briefly, a mass acquisition window from 200 to 2000 m/z and acquisition in positive and nega-
tive modes were used with a voltage of 1.2 kV in positive mode and −1.5 kV in negative mode and an acquisition 
time of 72 s.
Acquired spectral raw data were processed as described previously41 using an in-house bioinformatics 
platform based on XCMS42. With the use of predefined rejection lists and mass defect filters, this performed 
sample-specific mass re-calibration using predefined sets of internal standards and the removal of commonly 
present contaminant ions (often associated with plasticizers). The raw data were converted to.mzXML (using 
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MSconvert43 with peakpick level 1), parsed with R and 50 (scan from 20 to 70) spectra were averaged per sam-
ple using XCMS42, with a signal cutoff at 2000. The files were aligned using the XCMS42,44 grouping function 
using “mzClust” with a m/z-window of 22 ppm and a minimum coverage of 60%. Automated compound anno-
tation was carried out using both an exact mass search in compound libraries as well as applying the referenced 
Kendrick mass defect approach. Signal normalisation was performed by summing the intensities of all detected 
metabolites to a fixed value to produce a correction factor for the efficiency of ionisation.
As described previously45, exact masses were fitted to the lipid maps library and subsequently annotated to the 
peak. This converts initially roughly 4000 features (spectral regions associated with an analyte). These features 
were then considered within the parameters of our model, leading to 9 identified lipid species excluding isotopes.
Data modelling using Bayesian Statistical Methods. Model justification. The data recorded in the 
present study were naturally hierarchical: there were multiple measurements of each metabolite in each subject; 
yet for the present experiment, the aim was to identify those metabolites that were consistently affected by altitude 
across the entire study population. For this reason, we adopted a hierarchical approach to statistical modelling – 
specifically we fitted a hierarchical Bayesian model for each metabolite. This model comprised robust regression 
models (robust in that the residuals were modelled with a t-distribution46) for each binned 1H-NMR region or 
lipid variable at the participant level; the parameters from these regression analyses (specifically the slope and 
intercept, β1 and β0) were themselves modelled with normal distributions. Beyond the more general contrasts 
between using Bayesian over frequentist statistics (a recent discussion of which can be found here47), several 
advantages are specific to this application. First, a full distribution of credible regression lines for each metabolite 
in each subject was generated. Second, by fitting the complete hierarchical model in a single step, and estimating 
all distributions simultaneously, the estimates of the regression lines for each individual subject are constrained by 
the overarching distribution of the lines for that metabolite, a phenomenon known as shrinkage48,49. Hence slopes 
that are very unlikely for an individual subject (when the slopes for the remainder of the group are considered) 
are excluded unless compelling evidence exists in the data.
Despite the advantages, Bayesian statistics are computationally expensive. Therefore, simple frequentist hier-
archical models were fitted initially to all variables in order to identify those variables likely to be of interest for 
further modelling (in other words, those metabolites whose mean slopes were not zero). Only those metabolites 
whose mean slopes (from simple hierarchical modelling) were >±1.96 SDs from the mean were carried forward 
for full Bayesian modelling. These slopes were later compared to those derived using Bayesian methods and found 
to be reasonable estimates (Supplementary Fig. 5). Finally, Bayesian inference is somewhat different to frequentist 
approaches (e.g. there are no p-values). Hence, we adopted the criterion that metabolites should not include 0 in 
the high-density (95%) interval of the posterior distribution of z-transformed slopes. Together, this means that 
two levels of filtering were employed to ensure that only those slopes undergoing large degrees of change were 
considered.
Model details. The full Bayesian hierarchical model used here was described previously50. A model was fitted 
for every metabolite of interest. Data were z-transformed before fitting to reduce correlation between slopes and 
intercepts (which presents difficulties for the MCMC algorithm used in JAGS). Each model comprised linear 
sub-models of the standard form fitted to the normalised metabolite measurements for each subject, using a 
t-distribution for the residuals. The distribution of parameters for the t-distribution (σ and ν, the normality 
parameter) were estimated once per metabolite, not for each subject. The slopes and intercepts from each of these 
models were themselves modelled using normal distributions with parameters μ0 (the mean intercept), σ0 (the 
standard deviation of the intercepts), μ1 (the mean slope) and σ1 (the standard deviation of the slopes). Hence for 
each metabolite, the modelling process generated distributions for σ, v, μ0, σ0, μ1 and σ1 and – for each subject – 
distributions for β1 and β0. Our primary interest was in the distributions of μ1. Non-informative priors were used 
for all parameters. Remembering that all data were z-transformed prior to analysis, all σ were given a broad prior 
uniform distribution (with parameters L = 10−3 and H = 103 denoting the low and high limits), and ν a broad 
exponential distribution with a minimum of 1 and mean of 30 (at which point the distribution is approximately 
normal). For each normal distribution, μ was given a normal prior with parameters M = 0 and S = 10. Both the 
individual and group regression were assessed simultaneously and the individual regression lines constrained by 
the average regression lines.
Bayesian analysis was conducted using R and JAGS (Just Another Gibbs Sampler51 as described in Kruschke50). 
All code is available in supplementary materials.
Identified metabolites were presented with corresponding identification codes from the human metabolome 
database (HMDB). In the case of certain lipids where HMDB identification was not available, chemical entities of 
biological interest (ChEBI) were included.
Calculation of Absolute Changes. For the aqueous phase metabolites, the binned 1H-NMR spectral 
regions corresponding to an identified metabolite were assessed. The change in spectral intensity between LDN 
and EBC was calculated and from this the median % change derived. Given that this was a measure of spectral 
intensity, no absolute value such as concentration/ml plasma could be given for the change, instead arbitrary units 
were employed. The LDN and EBC values were also corrected to the LDN value, to give a normalised ratio of 
change. The same approaches were employed for assessment of the degree of change in lipid abundance, although 
this only included those definitively annotated lipids.
Statistical analysis. Analysis was performed in GraphPad Prism 7. The LDN and EBC values for SpO2 
and body weight data were abnormally distributed, as assessed using the D’Agostino-Pearson normality test. 
Therefore, a Wilcoxon matched-pairs signed rank test was employed for analysis.
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The Δ abundance of metabolites/lipids from LDN to EBC that were identified as undergoing large changes 
with ascent were plotted against the Δ SpO2 or body weight from LDN to EBC. For the aqueous fraction metab-
olites, this specifically refers to the Δ of spectral region intensity undergoing the greatest change, and for lipids, 
the definitively identified lipid variables. Data that followed a Gaussian distribution were tested using a Pearson 
Correlation Coefficient. A non-parametric Spearman rank correlation (two tailed) was applied for non-normally 
distributed data. If a significant relationship was identified, linear regression analysis was subsequently performed.
Results
Subject Characteristics, Body Weights and Arterial O2 Saturations. One hundred and ninety-eight 
participants (125 male, 73 female, 44 ± 14 (mean, ± SD) years of age, BMI 25.1 ± 3.2 kg/m2) participated in the 
expedition to EBC32.
The degree of hypoxic exposure experienced at altitude was reflected through progressive decreases in resting 
SpO2 with ascent. Overall, a 20.4% median decrease in SpO2 (n = 187, p < 0.0001) from 98% at LDN to 78% at 
EBC was observed (Fig. 1A). Body weight also progressively fell by a median of 3.7% (3 kg) between LDN and 
EBC (n = 157, p < 0.0001,) (Fig. 1B).
Plasma Metabolomic/Lipidomic Analysis. A total of 965 samples were obtained for metabolomic anal-
ysis on the aqueous fraction using NMR, and lipidomic analysis on the lipid fraction using DIMS. Between 182 
and 198 samples were analysed from each altitude location, totaling up to 5 samples per volunteer (1 per altitude 
location). The reason for differences in sample number was due to participants failing to arrive at the laboratory32 
or insufficient amounts of plasma being obtained for subsequent analysis. Bayesian robust hierarchical regression 
was used to identify metabolites that were robustly related to changes in altitude, from both the NMR and MS 
data. In particular, the focus was on those metabolites where the 95% high-density interval (a similar concept to 
95% confidence intervals in traditional statistics) of estimates of the overall slope of metabolite abundance vs. 
altitude did not contain 0.
Plasma aqueous fraction analysis. An example of the Bayesian model output for the overall group response 
is displayed in Fig. 2A,B, with examples of the individual response being displayed in Supplementary Fig. 6. A 
summary of aqueous metabolite changes are outlined in Table 1, with differences in peak intensity from LDN to 
EBC, expressed as a ratio, presented in Fig. 3A. The changes include a progressive decrease in glucose (D-Glucose 
HMDB00122), an increase in lactate (L-Lactic acid, HMDB00190) and a decrease in the branched-chain essential 
amino acid isoleucine (L-Isoleucine HMDB00172) with ascent to EBC. From the spectral regions corresponding 
to these metabolites, specific spectral peaks undergoing the largest degree of change were identified as: 1.31ppm 
for lactate (27.4% increase), 3.35ppm for glucose (52.4% decrease) and 0.92 ppm for isoleucine (60.5% decrease).
Plasma lipid fraction analysis. Two examples of the output from Bayesian hierarchical modelling of lipidomic 
data of the full participant group are presented in Fig. 2C,D. All lipid species identified as undergoing large 
changes with ascent (defined in the same way as for NMR spectral regions, see above) are summarised in Table 2, 
with the LDN:EBC ratio presented in Fig. 3B. The largest % lipid increase was identified as triglyceride (TG) with 
carbon chain: double bond ratios of 52:3, with a median increase from LDN to EBC of 53.9%. This occurred 
alongside an increased TG 52:4 (CHEBI: 84660) and in the most abundant non-esterified fatty acids within 
adipose tissue. This includes the saturated palmitic acid (16:0) (HMDB00220) and unsaturated linoleic (18:2) 
(HMDB00673) and oleic (18:1) (HMDB00207) acids. An increase was also observed in sphingomyelin (SM) 
34:2 (CHEBI:64587). The largest lipid % decrease was that of TG 48:1 (CHEBI: 85726), with a median decrease 
of 43.1%. This occurred alongside decreased TG 50:1 (50:1 (CHEBI: 84665) as well as phosphatidylcholine (PC) 
46:2 (CHEBI: 72430).
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Figure 1. Changes in physiological variables with ascent to EBC. This includes recording of resting arterial O2 
saturation (SpO2) (A) and body weight (kg) (B) at each time point upon ascent, with the midpoint representing 
the mean, ± SD. Data was tested using a Wilcoxon matched-pairs signed rank test between LDN to EBC, 
****p < 0.0001, n = 146–188.
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Correlation analysis. To assess whether a relationship existed between altitude dependent changes in 
metabolites/lipids from LDN to EBC and the specific physiological variables presented here, correlation plots 
were constructed.
Plots of changes in aqueous metabolites against body weight revealed a significant correlation between 
changes in glucose and body weight (p = 0.007), with decreased body weight being associated with decreased 
plasma glucose (Fig. 4A). Plots of the change in fatty acid vs. body weight from LDN to EBC revealed a signifi-
cant correlation between the unsaturated oleic (18:1) (p = 0.0127) and linoleic (18:2) (p = 0.0062) FA’s and body 
weight from LDN to EBC, with loss of body weight at altitude being associated with increasing levels of oleic and 
linoleic acids (Fig. 4B,C). No significant correlations were observed for changes in the other identified aqueous 
metabolites or lipids and body weight. Equally, no significance was observed between changes in any metabolite 
or lipid and SpO2.
Figure 2. An example of the full subject group response of aqueous metabolites or lipids that demonstrate a 
significant trend with increasing altitude, identified using Bayesian hierarchical modelling. Example plots of 
lactate (A) and isoleucine (B), with corresponding 1H-NMR regions, phosphocholine (PC) 46 carbons: 2 double 
bonds (46:2) (C) identified in negative ion mode and sphingomyelin (SM) 34:1 (D) identified in positive mode. 
Representative regression lines in blue have been drawn from the fitted distribution. This group distribution (all 
units) was informed from the most likely distribution at the level of the individual. Y axes metabolite units are 
arbitrary units, derived from the spectral intensity changing per km altitude.
Metabolite
Binned spectral 
region (ppm) LDN intensity (AU) EBC intensity (AU) Δ% LDN to EBC Slope (AU/km)
Increasing or  
decreasing with altitude
Isoleucine 0.92 0.012 0.0049 −60.5 −0.00142 Decreasing
Glucose 3.35 0.016 0.0081 −52.4 −0.0014 Decreasing
Lactate 1.31 0.057 0.0719 27.4 0.00361 Increasing
Table 1. Spectral intensity, % change and credible regression slope change of the 1H-NMR spectral regions 
identified as undergoing the largest degree of change with increasing altitude.
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Discussion
With exposure to reduced PiO2 during ascent to EBC, SpO2 fell proportionally by ~20%. We examined the met-
abolic response to this hypoxic exposure. We made efforts to distinguish this from responses to the inevitable 
potential confounders of an expedition of this nature, such as dietary changes. To this end, we used robust statis-
tical methods to identify metabolites that changed with altitude and hierarchical methods that captured the full 
structure of the data. That these findings are consistent with known biology serves to validate the methods used.
Specific changes in aqueous metabolites include a decrease in the glycolytic substrate glucose alongside an 
increase in the glycolytic product lactate. This pattern of change has long been associated with increased glyco-
lytic rate in the context of human cancer cell lines (e.g.52). In the context of high altitude exposure, the changes 
observed support prior observations of decreasing blood glucose concentrations, increasing muscle glycolytic 
intermediates and increasing blood lactate levels in lowlanders ascending to high altitude6,8. They are also in 
keeping with prior human, animal and cellular studies showing increased translocation of glucose transporters 
(GLUT-1 and GLUT-4) to the plasma membrane,53,54, upregulation of lactate dehydrogenase22,55 and a shunting of 
pyruvate away from entry into the TCA cycle and towards lactate formation9, all attributed to increased HIF-1α 
activity. Together, this therefore suggests the changes observed are a result of increased reliance upon anaerobic 
glycolysis at rest following ascent to high altitude. However, it is also worth noting that a decrease in plasma 
glucose may result from increased insulin secretion, which has been shown previously to occur upon altitude 
exposure6.
Lipidomic analysis revealed alterations to the main constituent of body fat, TGs. Specifically, circulating levels 
of TGs 52:4 and 52:3 increased whereas TGs 50:1 and 48:1 decreased. Those TGs containing 48–50 carbons are 
typically associated with de novo lipogenesis a process by which excess carbohydrates are converted to fatty acids 
and subsequently to TGs for storage45,56. This association has been demonstrated in human intervention studies45. 
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Figure 3. Alterations in aqueous metabolite and lipid abundance from London (LDN) to Everest base camp 
(EBC). Aqueous metabolite 1H-NMR spectral regions (A) and lipids (assessed using DIMS) (B) undergoing 
the largest degree of change with ascent to EBC, identified using Hierarchical Bayesian statistics. Values are 
corrected to LDN, and so are expressed as a ratio of LDN: EBC, with a value of 1 indicative of no change. 
Presented as minimum to maximum box and whisker plots, with the middle line representing the median and 
the box the interquartile range (25th to 75th percentiles).
Carbon chain length: 
double bond
Mode of ion 
detection
LDN abundance 
(AU)
EBC abundance 
(AU)
Δ% LDN 
to EBC
Δ Slope 
(AU/km)
Lipids increasing with ascent
Triglyceride 52:3 Positive 30.1 45.0 53.9 1.59
Triglyceride 52:4 Positive 10.72 16.50 53.7 0.529
Oleic acid 18:1 Negative 36.0 54.6 27.1 2.349
Linoleic acid 18:2 Negative 17.83 23.39 23.7 0.828
Sphingomyelin 34:1 Positive 26.8 30.8 15.7 0.001
Palmitic acid 16:0 Negative 110.4 116.7 12.4 2.176
Lipids decreasing with ascent
Triglyceride 48:1 Positive 4.25 2.42 −43.1 −0.334
Phosphatidylcholine 46:2 Negative 11.8 8.7 −25.0 −0.597
Triglyceride 50:1 Positive 10.95 9.69 −8.43 −0.524
Table 2. Abundance, % change and credible regression slope change for lipid variables identified as undergoing 
the largest degrees of change with increasing altitude.
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The fall in concentrations of TGs 48:1 and 50:1 with ascent to EBC may thus be linked with suppressed de novo 
lipogenesis, an effect known to be mediated by HIF-1α13,14. The increase in TGs 52:4 and 52:3 are likely a com-
pensatory change to retain a balance in circulating TGs. However, further analysis directly measuring de novo 
lipogenesis would be required to come to a firm conclusion regarding these changes.
The combination of decreased TGs alongside increased circulating levels of the most abundant fatty acids 
(including palmitic, linoleic and oleic acids), may be indicative of fat store mobilisation. This process can be 
induced via activation of the sympathetic nervous system (catecholamines activate cAMP-dependent phospho-
rylation of hormone sensitive lipase, which stimulates TG mobilisation57). Sympathetic activation is known to 
occur in response to hypobaric hypoxia, with an increase in efferent activity directed towards the heart, kidneys, 
vasculature and skeletal muscle58,59. Indeed, alterations in adrenaline/noradrenaline have been reported in previ-
ous investigations of the CXE expedition team, peaking at Namche Bazaar (3,500 m)6. Together this indicates that 
fat stores may become mobilised through hypoxic stimulated sympathetic activity, although again, further work 
would be required before a firm conclusion can be drawn.
Catecholamine stimulated breakdown of TG’s to release fatty acids can be impaired through the action of 
insulin. Increased circulating levels of fatty acids (notably palmitic, oleic and linoleic acids) are associated with 
insulin resistance60–62, including in models of obesity through a mechanism reliant upon c-Jun amino terminal 
kinases (JNKs)63. Indeed, in a linked study by our group, participants remaining at EBC or above for prolonged 
periods exhibited a substantial increase in insulin and C-peptide6. It is therefore possible that the mobilisation of 
fat stores indicated in the present study, resulting in an increase in circulating fatty acids, is a causative factor for 
the spike in insulin concentrations observed in response to longer term exposure6.
The rise in circulating fatty acid levels may also contribute to previous reports of impaired β-oxidation capac-
ity at high altitude5. Indeed, skeletal muscle mitochondrial respirometry carried out in a different cohort of low-
lander participants undertaking similar ascent to that reported here, revealed impairment of skeletal muscle fatty 
acid oxidative phosphorylation at EBC along with an intramuscular accumulation of fatty acid intermediates8.
Lipidomic analysis also revealed changes in key membrane components, including a decrease in PC 46:2. 
PCs are key constituents in the construction of lipoproteins, in particular very low density lipoprotein (VLDL)64, 
which is required for lipid transportation from the liver to cells. This observation may thus suggest that hypobaric 
hypoxia could affect this process. Disrupted lipoprotein transport, with inhibition of lipoprotein lipase activity in 
adipose tissue and pre-adipocytes, has been reported in response to chronic intermittent65 and acute hypoxia66, 
respectively.
An entirely novel change identified in the aqueous metabolites was a decrease in the essential branched-chain 
amino acid (BCAA) isoleucine with ascent. This is in contrast to prior studies investigating plasma responses of 
rats exposed to acute hypoxia (9.5% O2, 5–18 hrs)67 and in HeLa cells (1% O2)68, which reported an increase in 
isoleucine levels. This disparity may relate to differences in hypoxic exposure, with much more prolonged and 
progressive hypoxic exposure being adopted in our study, and the use of human participants.
In addition to their essential role in building muscle tissue, BCAA’s are regulators of key cellular signaling 
pathways including that of the mammalian target of rapamycin (mTOR), a central regulator of cell metabolism, 
Figure 4. Correlation of Δ glucose or fatty acids (FA) vs. Δ body weight. Glucose (A), unsaturated FA 18:1 (B) 
and 18:2 (C), shown as carbon: double bond ratio. Δ calculated as EBC-LDN. Correlation analysis performed 
using Pearson rank correlation coefficient. Significant (p < 0.01) correlations analysed further using linear 
regression.
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growth and survival69. The upregulation of mTOR signaling to induce protein synthesis is reliant upon an optimal 
ratio of BCAA’s70. In the present study, decreasing isoleucine levels were not matched by changes in the levels 
of leucine or valine to the same extent, as these amino acids did not meet the model criteria. Thus, whilst the 
consequences of the fall in circulating isoleucine in the context of hypoxic exposure remain to be determined, an 
impact upon muscle protein synthesis and potentially muscle catabolism, is likely. Indeed, mTOR protein levels 
have been reported to decrease in response to 7–9 days exposure to 4559 m in human vastus lateralis71.
In the present study body mass fell by an average of 3%, a finding in line with the commonly reported catabolic 
response to high altitude. First reported by Pugh in 196272, a fall in body mass with altitude exposure has since 
been linked to loss of lean mass attributed to muscle catabolism73,74. Attenuation of hypoxia-induced loss in body 
mass has been reported with BCAA supplementation75, whereas supplementation solely with leucine was not 
effective76. Together with the results of the present study, this may therefore suggest that inclusion of isoleucine in 
dietary supplementation may be crucial if muscle catabolism is to be mitigated against.
To investigate whether metabolite changes were associated with either the degree of change in SpO2 or body 
weight with ascent, correlation analyses between metabolites/lipids and these factors were performed. This is in 
line with the notion that whilst changes in oxygen delivery are an essential part of hypoxic acclimatisation, alter-
ations to metabolic processes modifying oxygen use at a cellular level are crucial5,8. Indeed, mechanisms altering 
oxygen delivery do not account for inter-individual performance at altitude77,78 and the hypoxic phenotypes of 
acute mountain sickness does not correlate well with degree of SpO279. Correlation analysis did reveal that loss 
of body weight was associated with decreasing plasma glucose and increasing oleic and linoleic acids. It is not 
possible to determine whether this association may be caused by dietary alterations or loss of appetite. However, 
it is important to note that the loss of body weight was associated with increasing altitude exposure, which is in 
line with previous work outlining that appetite suppression at altitude is a hypoxic driven response mediated by 
changes in leptin signaling80,81. The present work thus highlights the importance of body mass changes with alti-
tude in relation to metabolic shifts.
Study limitations. In comparison to previous studies examining metabolic acclimatisation of human sub-
jects to high altitude hypoxia both in the field and laboratory, this study is unique in its scale and design. To 
enable success, it required the adoption of a pragmatic approach, the nature of which precluded the addition of 
a control group. Whilst the insult of hypobaric hypoxia was undoubtedly severe at the altitude reached, it must 
be noted that the effects reported may have been influenced by other environmental factors, such as a change in 
temperature and UV exposure.
Other factors that are known to impact metabolic function that may have affected the metabolomic/lipidomic 
profiles are potential alterations to exercise and diet. Daily activity data was not recorded, however all subjects 
underwent identical ascent profiles for which the exercise burden each day was low in both intensity and dura-
tion, as demonstrated by trekking distance/day detailed in the methods. Given that the cohort of subjects were 
healthy and active people, habitually partaking in exercise as part of normal life thus makes acute changes in 
exercise unlikely. In addition, the timing of the blood draw (rest day morning, minimum 16 hrs post exercise in 
a fasted, rested state), again makes effects of an exercise insult upon resulting metabolite/lipid analysis unlikely.
Dietary changes are another potential confounding factor, given that food was consumed ad libitum and was lim-
ited to that available in Kathmandu and the remote trekking locations. Had dietary effects been present, they would 
most likely become apparent between London and Kathmandu, and following this Kathmandu to Namche. Initial 
analysis performed on the data sets using PLS-DA models demonstrated that the most accurate, robust separation 
in lipid positive mode was apparent between London and EBC rather than the London, Kathmandu and Namche 
comparisons (Supplementary Fig. 7). In addition, the focus of the Bayesian model output is the regression line, along 
which is plotted each altitude location. Whilst fluctuations are apparent between altitude locations, the credible 
regression lines are shown to be robust to relatively minor shifts. Together, this suggests the major factor in influ-
encing the direction of the resulting trend is altitude. However, we would recommend that future studies examining 
metabolomic/lipdomic profiles should include a standardised dietary intake, as well as a daily recording of exercise.
Finally, limitations of our statistical approach must be noted. The benefits of the robust Bayesian modelling 
approach have been outlined in the methods section. The downside of this is the vast computational power 
required. A compromise was therefore required to practically obtain results in a reasonable time scale, resulting 
in the model parameters outlined in the methods section. In addition to restricting computational power require-
ments, this approach also helped to focus analysis upon the ‘big changers’ within the profile. The restrictions placed 
upon the selection of those metabolites taken forward for Bayesian modelling may have limited metabolite/lipid 
identification. This was particularly apparent in the aqueous metabolite results whereby only 3 metabolites were 
taken forward. Such a compromise was considered worthwhile to ensure confidence in the data interpretation.
Conclusions
In summary, this study is the first to profile the systemic metabolic responses to increasing altitude in healthy 
humans, using untargeted metabolomics and lipidomics. Alterations identified in the aqueous fraction included 
the novel finding of decreasing isoleucine with ascent, with possible implications for muscle catabolism, alongside 
lactate and glucose changes that were in line with the well-documented increased reliance upon glycolytic energy 
metabolism. Fluctuations in the lipid profile with ascent suggest increased mobilisation of lipid stores and sup-
pressed de novo lipogenesis. This occurred alongside changes to lipids that are essential membrane components, 
particularly those involved in the lipoprotein transport system. This study has therefore highlighted potential 
metabolic biomarkers for progressive hypoxic exposure in healthy humans.
Ethics approval and consent to participate. The study design, risk management plan and individual 
protocols for the Caudwell Xtreme Everest (CXE) Expedition were approved by the University College London 
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(UCL) Research Ethics Committee (in accordance with the declaration of Helsinki). Both verbal and written 
informed consent was obtained from all participants.
Data Availability
The datasets used and/or analysed during the current study are available from the corresponding authors on 
reasonable request.
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